Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
https://doi.org/10.14341/DM2014181-84
Abstract
The introduction of DPP-4 inhibitors substantially increased therapeutic options for type 2 diabetes mellitus (T2DM). The unique mechanism of action allows using these agents both as monotherapy and in combination with conventional anti-diabetes drugs. Evidence base for efficacy and safety of DPP-4 inhibitors deepens every year, but to date only a few studies addressed direct comparison between individual agents within this pharmacological class.
Current article presents data from the studies comparing vildagliptin with other DPP-4 inhibitors, as well as GLP-1 agonists.
Current article presents data from the studies comparing vildagliptin with other DPP-4 inhibitors, as well as GLP-1 agonists.
About the Author
Elena Valer'evna Biryukova
Moscow State University of Medicine and Dentistry, Moscow
Russian Federation
MD, PhD, Professor, Endocrinology Department
Russian Federation
MD, PhD, Professor, Endocrinology Department
References
1. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. Diabetic Med 2007;24(9):955-961. Available from: http://doi.wiley.com/10.1111/j.1464-5491.2007.02191.x doi: 10.1111/j.1464-5491.2007.02191.x.
2. Tahrani AA, Piya MK, Barnett AH. Drug evaluation: Vildagliptin-metformin single-tablet combination. Adv Therapy 2009;26(2):138-154. Available from: http://link.springer.com/10.1007/s12325-009-0010-0 doi: 10.1007/s12325-009-0010-0.
3. Marfella R, Barbieri M, Grella R, Rizzo MR, Nicoletti GF, Paolisso G. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. Journal of Diabetes and its Complications 2010;24(2):79-83. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1056872709000075 doi: 10.1016/j.jdiacomp.2009.01.004.
4. Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.. J Am Pharm Assoc (2003) 2009;49 Suppl 1(Suppl. 1):16-29. Available from: http://www.nlm.nih.gov/medlineplus/diabetesmedicines.html PubMed PMID: 19801361. doi: 10.1331/JAPhA.2009.09078.
5. He YL, Yamaguchi M, Ito H, Terao S, Sekiguchi K. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes. Int J Clin Pharmacol Ther 2010;48(09):582-595. Available from: http://www.dustri.com/article_response_page.html?artId=7896&doi=10.5414/CPP48582&L=0 PubMed PMID: 20860912. doi: 10.5414/CPP48582.
6. Ischiropoulos H. Biological Tyrosine Nitration: A Pathophysiological Function of Nitric Oxide and Reactive Oxygen Species. Archives of Biochemistry and Biophysics 1998;356(1):1-11. Available from: http://linkinghub.elsevier.com/retrieve/pii/S000398619890755X PubMed PMID: 9681984. doi: 10.1006/abbi.1998.0755.
7. Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of Dipeptidyl Peptidase-IV Inhibition. Diabetes Care 2012;35:2076-2082. Diabetes Care;37(2):587-588. Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/dc14-er02a doi: 10.2337/dc14-er02a.
8. Sakamoto M, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).. Cardiovasc Diabetol 2012;11:92. Available from: http://www.cardiab.com/content/11//92 PubMed PMID: 22867630. doi: 10.1186/1475-2840-11-92.
9. Aroda VR, Henry RR, Han J, Huang W, DeYoung MB, Darsow T, et al. Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review. Clinical Therapeutics 2012;34(6):1247-1258. Available from: http://dx.doi.org/10.1016/j.clinthera.2012.04.013
Review
For citations:
Biryukova E.V. Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications. Diabetes mellitus. 2014;17(1):81-84. (In Russ.) https://doi.org/10.14341/DM2014181-84
Views:
5104
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
